Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Epilepsy DataOvid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.There were no treatment-related adverse events in the 7 mg cohort, and 19 unrelated adverse events, all of which were mild and transient.Additionally, the company plans to expand OV329’s development to include tuberous sclerosis complex seizures and infantile spasms, with a proof-of-concept study for TSC expected to begin in the fourth quarter of 2026.The ...